A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

Summary

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). These participants are at high risk for progression of kidney disease, which can result in end-stage renal failure.

Timeline

Start

2019-09-30

Primary completion

2022-03-17

Completion

2023-06-27

Drugs

Indications